ArticleEye (London, England)2026
Recent vaccination exposure and central serous chorioretinopathy.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral serous chorioretinopathy (CSCR) is characterised by choroidal hyperpermeability and potential dysregulation of inflammatory cytokines. Because vaccination transiently activates cytokine pathways, we assessed whether vaccination is associated with incident CSCR.
methodsWe performed a case-control study in the Mass General Brigham database among adults 18-60 years. CSCR cases were matched 4:1 to controls by demographics, systemic conditions relevant to vaccination likelihood or infection susceptibility, CSCR risk factors, healthcare utilisation and index month/year. Vaccination within 90 days before index was evaluated overall, by vaccine category, and by time window (1-10, 11-45, and 46-90 days before index); odds ratios (ORs) were estimated.
resultsAmong 3 205 CSCR cases, 66 (2.1%) had recorded vaccination within 90 days before index compared with 232 (1.8%) of 12 753 controls (OR 1.14, 95% CI 0.86-1.50; P = 0.37). No associations were observed for influenza (OR 1.09, 95% CI 0.74-1.60; P = 0.67), COVID-19 (OR 1.00, 95% CI 0.37-2.66; P = 0.99), or tetanus-containing vaccines (OR 1.20, 95% CI 0.73-1.95; P = 0.48). Vaccination within 1-10 days before index was associated with higher odds of CSCR (OR 2.00, 95% CI 1.02-3.89; P = 0.043). Case-crossover analysis showed similar temporal clustering (OR 3.25, 95% CI 1.06-9.97; P = 0.039).
conclusionsVaccination within 1-10 days before index was associated with higher odds of CSCR, although vaccination within 90 days was not. These findings do not support changes to vaccination practice for patients at risk of CSCR, but highlight the need for larger studies with complete vaccine capture to evaluate CSCR risk during the acute post-vaccination period.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.